MedCity News May 20, 2020
The two plan to identify and analyze sources of real-world data that they can use to characterize populations of patients with Covid-19, their use of medicines, risk factors and to characterize potential interventions.
A firm that generates real-world evidence for the life sciences industry is teaming up with the Food and Drug Administration in a push to use real-world data to understand and respond to Covid-19.
New York-based Aetion said Tuesday that the partnership with the FDA would focus on assessing and analyzing real-world data sets to generate information about the course and treatment of the disease, as well as diagnostic patterns, using the company’s Evidence Platform system.
The effort will involve identifying and analyzing sources of data to characterize...
Today's Sponsors
Today's Sponsor